Johnson & Johnson's (JNJ) Janssen-Cilag International unit said Wednesday that the European Commission has approved an indication extension of Imbruvica, or ibrutinib, in frontline mantle cell lymphoma, or MCL, an aggressive and incurable form of blood cancer.
The approved regimen includes ibrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone alternating with R-DHAP or R-DHAOx without ibrutinib, followed by ibrutinib monotherapy to treat adults with previously untreated MCL who are eligible for autologous stem cell transplant, the company said.
The approval was backed by data from a phase 3 trial conducted by the European MCL Network, the company added.
After a median follow-up of 55 months, the study showed that ibrutinib combined with chemoimmunotherapy led to "significantly superior" failure-free survival even without the need for transplant, the company said.
Price: 167.26, Change: -0.67, Percent Change: -0.40
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.